Proof LinePeptidesKisspeptin-1010 mgResearch use onlyPowered by Align Biosciences
Kisspeptin-10
10 mg
$73.99 CAD
Proof LinePeptidesGLP-320 mgResearch use onlyPowered by Align Biosciences
GIP, GLP-1 and glucagon receptor triple agonist · Research reagent
GLP-3
GLP-3 is a nickname for retatrutide. It targets three receptors, GLP-1, GIP and glucagon, and is being studied in clinical trials on metabolism and body weight.
$141.99 CAD
· $7.10 / mgIn stockVial discount: 5% off at 3, 10% at 5, 20% at 10 eligible single vials, any mix. Applied automatically in the cart.
In stock · Ships next business day from Toronto
Interac e-Transfer
$9.99 shipping, free from $250 · Ships from Toronto · Canada only
Shipping and returns: Ships next business day from Toronto · $9.99 shipping, free from $250 · Arrives right or we make it right
For research use only. Not for human consumption.
Independent lab report
Lab report for this format available on request.
About GLP-3
GLP-3, also published as Retatrutide and LY3437943, is catalogued here as: GIP, GLP-1 and glucagon receptor triple agonist. GLP-3 is a nickname for retatrutide, studied in adults for metabolic and body-weight outcomes. It targets GLP-1, GIP and glucagon receptors: three targets, not three established benefits. GLP-3 is the informal catalogue name used here for retatrutide, a multi-receptor peptide agonist studied in metabolic research. The “3” refers informally to three named targets: GLP-1, GIP and glucagon receptors. GLP-3 is not itself a scientific receptor name, and receptor activity and clinical outcomes are separate questions. GLP-3 is a nickname for retatrutide. It targets three receptors, GLP-1, GIP and glucagon, and is being studied in clinical trials on metabolism and body weight.
Metabolic research of this kind uses randomized, placebo-controlled trials with defined populations and durations, measuring body-weight endpoints together with adverse events such as gastrointestinal symptoms and heart-rate changes.
A 2023 phase 2 randomized, placebo-controlled trial in 338 adults over 48 weeks reported lower body-weight outcomes in the study arms, along with gastrointestinal adverse events and heart-rate increases.
Human trial literature: Jastreboff et al. (NEJM, 2023) randomized 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week phase 2 trial. Receptor activity concerns metabolic signalling; measured weight change is a separate endpoint, not proof of an appetite mechanism or a PLP product effect.
Proof Line Peptides lists GLP-3 as a vial in 10 mg, 20 mg and 30 mg. Prices are shown in Canadian dollars, and orders ship from Toronto by tracked Canadian service.
The matched PPB Analytical Inc. report for GLP-3 10 mg (report 2026030632-01, dated Apr. 02, 2026) records 100.00% purity. It documents the supplier sample sent for testing, not every shipped lot, and the original PDF is linked on this page.
Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.